Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Plus Capecitabine Maintenance in mCRC
NCT05451719Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, randomised, open-label trial of fruquintinib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-free Survival at 24 months. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05451719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451719.